AZURITY PHARMACEUTICALS
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 02 Sept 2026)
What this means for you
Registered since 24 Nov 2020. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 24 Nov 2030: the §8 & §9 renewal).
Record
- Serial number
- 88452967
- Registration number
- 6206671
- Mark type
- Design + words
- Filed
- 30 May 2019
- Published for opposition
- 03 Mar 2020
- Registered
- 24 Nov 2020
- Next maintenance filing
- §8 & §9 renewal, due by 24 Nov 2030 (grace period to 24 May 2031)
- Attorney of record
- Douglas R. Wolf
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders
Owner
- AZURITY PHARMACEUTICALS, INC., WOBURN, MA, US
- AZURITY PHARMACEUTICALS, INC., WOBURN, MA, US
- CutisPharma, Inc., Woburn, MA, US
- CutisPharma, Inc., Woburn, MA, US
Prosecution history
- 02 Sept 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 02 Sept 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 01 Sept 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 04 Jun 2026 — TEAS SECTION 8 & 15 RECEIVED
- 24 Nov 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 19 Mar 2025 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 24 Nov 2020 — REGISTERED-PRINCIPAL REGISTER
- 22 Oct 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Oct 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Oct 2020 — STATEMENT OF USE PROCESSING COMPLETE
- 06 Oct 2020 — USE AMENDMENT FILED
- 20 Oct 2020 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Oct 2020 — TEAS STATEMENT OF USE RECEIVED
- 29 Apr 2020 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 28 Apr 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT